Market News AIOpen the app

Palvella Therapeutics, Inc. will hold a call to talk about its new QTORIN program and a treatment for Extramammary Paget's disease.

ProductRead the original at SEC EDGAR
Good for PVLA

Palvella added a third QTORIN program candidate for a rare skin disease, giving it another possible treatment to develop. It is still at an early stage, but this expands the company's drug development work.

PVLA · Palvella Therapeutics, Inc.

AI read · Good for PVLA

The AI's read

A third program gives Palvella another chance to develop a treatment for a rare skin disease. The presentation lists early studies and an IND filing as plans, not completed steps. No trial results or approval are reported, so this is an early step, but it adds another possible treatment to develop.

Get alerts for PVLA

Follow Palvella Therapeutics, Inc. (PVLA) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for PVLA
Free on the App Store and Google Play, or on the web.